UGT1A1 genotype influences clinical outcome in patients with intermediate-risk acute myeloid leukemia treated with cytarabine-based chemotherapy.
Díaz-Santa J, Rodríguez-Romanos R, Osca G, Pratcorona M, Garrido A, Coll R, Moret C, Escoda L, Tormo M, Heras I, Arnan M, Vives S, Salamero O, Lloveras N, Bargay J, Sampol A, Cruz D, Garcia A, Quiñones T, Esteve J, Sierra J, Gallardo D; on the behalf of CETLAM Group.
Díaz-Santa J, et al. Among authors: moret c.
Leukemia. 2020 Nov;34(11):2925-2933. doi: 10.1038/s41375-020-0784-2. Epub 2020 Mar 9.
Leukemia. 2020.
PMID: 32152464